CN1879839A - 一种治疗高脂血症的蒙药保利尔及其制备方法 - Google Patents
一种治疗高脂血症的蒙药保利尔及其制备方法 Download PDFInfo
- Publication number
- CN1879839A CN1879839A CNA2006100804253A CN200610080425A CN1879839A CN 1879839 A CN1879839 A CN 1879839A CN A2006100804253 A CNA2006100804253 A CN A2006100804253A CN 200610080425 A CN200610080425 A CN 200610080425A CN 1879839 A CN1879839 A CN 1879839A
- Authority
- CN
- China
- Prior art keywords
- radix
- parts
- fructus
- poly
- standby
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 53
- 201000005577 familial hyperlipidemia Diseases 0.000 title claims description 16
- 238000000034 method Methods 0.000 title description 13
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 16
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 239000000843 powder Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 241000628997 Flos Species 0.000 claims description 15
- 210000000582 semen Anatomy 0.000 claims description 15
- 244000153234 Hibiscus abelmoschus Species 0.000 claims description 14
- 239000009636 Huang Qi Substances 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 12
- 235000019634 flavors Nutrition 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 6
- 239000011812 mixed powder Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 241000132446 Inula Species 0.000 claims description 3
- 241000498779 Myristica Species 0.000 claims description 3
- 241000545442 Radix Species 0.000 claims description 3
- 241000001522 Terminalia chebula Species 0.000 claims description 3
- 240000001972 Gardenia jasminoides Species 0.000 claims 1
- 244000111489 Gardenia augusta Species 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 235000009421 Myristica fragrans Nutrition 0.000 abstract 2
- 241001647745 Banksia Species 0.000 abstract 1
- 206010004542 Bezoar Diseases 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 241000402754 Erythranthe moschata Species 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 244000270834 Myristica fragrans Species 0.000 abstract 1
- 241000220317 Rosa Species 0.000 abstract 1
- 240000000513 Santalum album Species 0.000 abstract 1
- 235000008632 Santalum album Nutrition 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 239000001115 mace Substances 0.000 abstract 1
- 239000001702 nutmeg Substances 0.000 abstract 1
- 244000138993 panchioli Species 0.000 abstract 1
- 210000003296 saliva Anatomy 0.000 abstract 1
- 239000002023 wood Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 18
- 230000000694 effects Effects 0.000 description 15
- 241000700159 Rattus Species 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 208000031226 Hyperlipidaemia Diseases 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 108010023302 HDL Cholesterol Proteins 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000000341 volatile oil Substances 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 4
- 238000010241 blood sampling Methods 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 230000035602 clotting Effects 0.000 description 4
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 210000002969 egg yolk Anatomy 0.000 description 4
- 230000003203 everyday effect Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 208000035150 Hypercholesterolemia Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000013345 egg yolk Nutrition 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- JSNRRGGBADWTMC-UHFFFAOYSA-N (6E)-7,11-dimethyl-3-methylene-1,6,10-dodecatriene Chemical compound CC(C)=CCCC(C)=CCCC(=C)C=C JSNRRGGBADWTMC-UHFFFAOYSA-N 0.000 description 2
- 239000001306 (7E,9E,11E,13E)-pentadeca-7,9,11,13-tetraen-1-ol Substances 0.000 description 2
- YQUVCSBJEUQKSH-UHFFFAOYSA-N 3,4-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 229930183118 Tanshinone Natural products 0.000 description 2
- YRKCREAYFQTBPV-UHFFFAOYSA-N acetylacetone Chemical compound CC(=O)CC(C)=O YRKCREAYFQTBPV-UHFFFAOYSA-N 0.000 description 2
- PXOYOCNNSUAQNS-AGNJHWRGSA-N alantolactone Chemical compound C1[C@H]2OC(=O)C(=C)[C@H]2C=C2[C@@H](C)CCC[C@@]21C PXOYOCNNSUAQNS-AGNJHWRGSA-N 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 229940000406 drug candidate Drugs 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- BNWJOHGLIBDBOB-UHFFFAOYSA-N myristicin Chemical compound COC1=CC(CC=C)=CC2=C1OCO2 BNWJOHGLIBDBOB-UHFFFAOYSA-N 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- NDVASEGYNIMXJL-UHFFFAOYSA-N sabinene Chemical compound C=C1CCC2(C(C)C)C1C2 NDVASEGYNIMXJL-UHFFFAOYSA-N 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- KWFJIXPIFLVMPM-KHMAMNHCSA-N (+)-alpha-santalene Chemical compound CC(C)=CCC[C@]1(C)[C@@H]2C[C@H]3[C@@H](C2)[C@@]13C KWFJIXPIFLVMPM-KHMAMNHCSA-N 0.000 description 1
- NDVASEGYNIMXJL-NXEZZACHSA-N (+)-sabinene Natural products C=C1CC[C@@]2(C(C)C)[C@@H]1C2 NDVASEGYNIMXJL-NXEZZACHSA-N 0.000 description 1
- PGBNIHXXFQBCPU-ILXRZTDVSA-N (-)-beta-santalene Chemical compound C1C[C@H]2C(=C)[C@@](CCC=C(C)C)(C)[C@@H]1C2 PGBNIHXXFQBCPU-ILXRZTDVSA-N 0.000 description 1
- SNKFFCBZYFGCQN-PDVBOLEISA-N (2r)-2-[(e)-3-[(2r,3r)-3-[(1r)-1-carboxy-2-(3,4-dihydroxyphenyl)ethoxy]carbonyl-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-1-benzofuran-4-yl]prop-2-enoyl]oxy-3-(3,4-dihydroxyphenyl)propanoic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=2[C@@H](C(=O)O[C@H](CC=3C=C(O)C(O)=CC=3)C(O)=O)[C@@H](OC=2C(O)=CC=1)C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 SNKFFCBZYFGCQN-PDVBOLEISA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- JSNRRGGBADWTMC-QINSGFPZSA-N (E)-beta-Farnesene Natural products CC(C)=CCC\C(C)=C/CCC(=C)C=C JSNRRGGBADWTMC-QINSGFPZSA-N 0.000 description 1
- 241000208340 Araliaceae Species 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000018152 Cerebral disease Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- GVKKJJOMQCNPGB-JTQLQIEISA-N Cryptotanshinone Chemical compound O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1[C@@H](C)CO2 GVKKJJOMQCNPGB-JTQLQIEISA-N 0.000 description 1
- GVKKJJOMQCNPGB-UHFFFAOYSA-N Cryptotanshinone Natural products O=C1C(=O)C2=C3CCCC(C)(C)C3=CC=C2C2=C1C(C)CO2 GVKKJJOMQCNPGB-UHFFFAOYSA-N 0.000 description 1
- XJMPAUZQVRGFRE-SCHFUKFYSA-N Gardenoside Natural products O=C(OC)C=1[C@H]2[C@H]([C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O3)OC=1)[C@@](O)(CO)C=C2 XJMPAUZQVRGFRE-SCHFUKFYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- PDEQKAVEYSOLJX-UHFFFAOYSA-N Hexahydronerolidol Natural products C1C2C3(C)C2CC1C3(C)CCC=C(CO)C PDEQKAVEYSOLJX-UHFFFAOYSA-N 0.000 description 1
- 241000521257 Hydrops Species 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- ALHUZKCOMYUFRB-OAHLLOKOSA-N Muscone Chemical group C[C@@H]1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-OAHLLOKOSA-N 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- XWQLUVQFUZQPDY-UHFFFAOYSA-N Sesquifenchene Natural products CC(=CCCC1(C)C2CCC1C(=C)C2)C XWQLUVQFUZQPDY-UHFFFAOYSA-N 0.000 description 1
- 241000282894 Sus scrofa domesticus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- PXOYOCNNSUAQNS-UHFFFAOYSA-N alantolactone Natural products C1C2OC(=O)C(=C)C2C=C2C(C)CCCC21C PXOYOCNNSUAQNS-UHFFFAOYSA-N 0.000 description 1
- PDEQKAVEYSOLJX-AIEDFZFUSA-N alpha-Santalol Natural products CC(=CCC[C@@]1(C)[C@H]2C[C@@H]3[C@H](C2)[C@]13C)CO PDEQKAVEYSOLJX-AIEDFZFUSA-N 0.000 description 1
- KWFJIXPIFLVMPM-BSMMKNRVSA-N alpha-santalene Natural products C(=C\CC[C@]1(C)C2(C)[C@H]3[C@@H]2CC1C3)(\C)/C KWFJIXPIFLVMPM-BSMMKNRVSA-N 0.000 description 1
- PDEQKAVEYSOLJX-BKKZDLJQSA-N alpha-santalol Chemical group C1C2[C@]3(C)C2C[C@H]1[C@@]3(C)CC/C=C(CO)/C PDEQKAVEYSOLJX-BKKZDLJQSA-N 0.000 description 1
- KQAZVFVOEIRWHN-UHFFFAOYSA-N alpha-thujene Natural products CC1=CCC2(C(C)C)C1C2 KQAZVFVOEIRWHN-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- OJYKYCDSGQGTRJ-INLOORNJSA-N beta-Santalol Natural products C1C[C@H]2C(=C)[C@](CC\C=C(CO)/C)(C)[C@@H]1C2 OJYKYCDSGQGTRJ-INLOORNJSA-N 0.000 description 1
- YSNRTFFURISHOU-UHFFFAOYSA-N beta-farnesene Natural products C=CC(C)CCC=C(C)CCC=C(C)C YSNRTFFURISHOU-UHFFFAOYSA-N 0.000 description 1
- OJYKYCDSGQGTRJ-GQYWAMEOSA-N beta-santalol Chemical compound C1C[C@H]2C(=C)[C@@](CC/C=C(CO)/C)(C)[C@@H]1C2 OJYKYCDSGQGTRJ-GQYWAMEOSA-N 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- -1 lauro lene Chemical compound 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- XJMPAUZQVRGFRE-AYDWLWLASA-N methyl (1s,4as,7s,7as)-7-hydroxy-7-(hydroxymethyl)-1-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4a,7a-dihydro-1h-cyclopenta[c]pyran-4-carboxylate Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1[C@](C=C2)(O)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O XJMPAUZQVRGFRE-AYDWLWLASA-N 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- ALHUZKCOMYUFRB-UHFFFAOYSA-N muskone Natural products CC1CCCCCCCCCCCCC(=O)C1 ALHUZKCOMYUFRB-UHFFFAOYSA-N 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 229940054441 o-phthalaldehyde Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 229930006696 sabinene Natural products 0.000 description 1
- STCJJTBMWHMRCD-UHFFFAOYSA-N salvianolic acid B Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=O)C=Cc2cc(O)c(O)c3OC(C(C(=O)OC(Cc4ccc(O)c(O)c4)C(=O)O)c23)c5ccc(O)c(O)c5 STCJJTBMWHMRCD-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000194 supercritical-fluid extraction Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
组别与剂量(g/kg) | 动物数(n) | 血清中TC含量(mmcl/L;±SD) |
正常对照组保利尔4.502.251.13 | 10101010 | 3.77±0.923.62±0.543.62±0.603.76±0.84 |
组别与剂量(g/kg) | 动物数(n) | 血清中TC含量(mmcl/L;±SD) |
正常对照组高脂模型组保利尔4.502.251.13 | 1010101010 | 3.77±0.92△△△7.92±0.986.79±0.83**5.96±1.02***6.26±0.92*** |
组别与剂量(g/kg) | 动物数(n) | 血清各种脂质含量(mmcl/L;±SD) | ||
TC | TC | HDL-C | ||
正常对照组高脂模型组保利尔4.502.251.13 | 88888 | 8.48±0.81△△△13.56±2.749.50±0.95**9.44±0.66**9.57±0.55** | 2.23±0.80△△4.33±1.372.52±1.05**2.71±0.50**3.12±0.59* | 0.83±0.11△△0.64±0.090.82±0.12**0.90±0.08**0.70±0.08* |
组别与剂量(g/kg) | 动物数(n) | 全血粘度比 | 血浆粘度(比) | 红细胞压积(%) | |
高切值≤2S) | 低切值≤0.35) | ||||
正常对照组高脂模型组保利尔4.502.25 | 8888 | 8.52±0.72△△△12.51±2.638.48±0.99**9.55±0.89* | 13.81±2.60△△22.53±4.7314.35±1.49***15.71±3.13** | 1.70±0.071.92±0.29 | 52.04±1.84△△ △56.81±1.8556.81±1.85 |
1.13 | 8 | 9.55±0.94 | 15.41±2.52** | 1.80±0.191.74±0.081.78±0.12 | 52.34±1.66***53.07±2633** |
组别与剂量(g/kg) | 动物数(n) | 5min血小板聚集率(ADP)(%,±SD) |
正常对照组保利尔4.502.251.13 | 10101010 | 53.40±9.3128.39±12.59***27.69±13.35***34.53±9.88*** |
组别与剂量(g/kg) | 动物数(n) | 凝血时间(min,±SD) |
正常对照组保利尔4.502.251.13 | 10101010 | 0.75±0.351.20±0.43*1.33±0.52**1.17±0.53* |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100804253A CN100409880C (zh) | 2006-05-15 | 2006-05-15 | 一种治疗高脂血症的蒙药保利尔及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2006100804253A CN100409880C (zh) | 2006-05-15 | 2006-05-15 | 一种治疗高脂血症的蒙药保利尔及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1879839A true CN1879839A (zh) | 2006-12-20 |
CN100409880C CN100409880C (zh) | 2008-08-13 |
Family
ID=37518340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2006100804253A Active CN100409880C (zh) | 2006-05-15 | 2006-05-15 | 一种治疗高脂血症的蒙药保利尔及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100409880C (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102698185A (zh) * | 2012-07-09 | 2012-10-03 | 宋永心 | 一种治疗高血脂症的藏药及其制备方法 |
CN104258135A (zh) * | 2014-09-23 | 2015-01-07 | 苏州市天灵中药饮片有限公司 | 用于降血压降血脂的保健软胶囊及其制备方法 |
CN106109645A (zh) * | 2016-07-03 | 2016-11-16 | 张俊清 | 一种治疗牛热射病的蒙药组合物 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1356138A (zh) * | 2001-09-27 | 2002-07-03 | 孔金立 | 一种主治专治老年人心脑血管疾病的药物 |
-
2006
- 2006-05-15 CN CNB2006100804253A patent/CN100409880C/zh active Active
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102698185A (zh) * | 2012-07-09 | 2012-10-03 | 宋永心 | 一种治疗高血脂症的藏药及其制备方法 |
CN102698185B (zh) * | 2012-07-09 | 2013-06-19 | 宋永心 | 一种治疗高血脂症的藏药及其制备方法 |
CN104258135A (zh) * | 2014-09-23 | 2015-01-07 | 苏州市天灵中药饮片有限公司 | 用于降血压降血脂的保健软胶囊及其制备方法 |
CN106109645A (zh) * | 2016-07-03 | 2016-11-16 | 张俊清 | 一种治疗牛热射病的蒙药组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN100409880C (zh) | 2008-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1994451B (zh) | 治疗抑郁症的中药组合物及其制备方法和其应用 | |
CN102671137B (zh) | 一种治疗糖尿病肾病的药物组合物及其制备方法 | |
CN1058614C (zh) | 植物制剂组合物 | |
CN106362020B (zh) | 一种具有改善通便作用的松花粉组合物及其制备方法 | |
CN101953918A (zh) | 一种治疗心脑血管疾病的中药组合物 | |
CN105935374A (zh) | 全麻素在制备治疗消渴症药物中的应用 | |
CN101612196B (zh) | 一种防治心脑血管疾病的中药组合物及其应用 | |
CN100518809C (zh) | 一种治疗糖尿病肾病的药物组合及其制备方法 | |
CN100409880C (zh) | 一种治疗高脂血症的蒙药保利尔及其制备方法 | |
CN105998194A (zh) | 一种抗血栓的药物 | |
CN107773679A (zh) | 一种辅助降血脂、辅助溶解血栓的组合物及其制备工艺 | |
CN105943617A (zh) | 全麻素在制备抗肝炎药物中的应用 | |
CN104984296A (zh) | 一种治疗女性更年期综合症的药物组合物及其制备方法 | |
CN104645015A (zh) | 一种治疗血管性痴呆的中药复方制剂及其制备方法 | |
CN1267086C (zh) | 一种能调节血糖、治疗糖尿病的制剂的制备方法 | |
CN1440804A (zh) | 一种降血脂的中药 | |
CN1253190C (zh) | 一种治疗糖尿病的药物 | |
CN100488546C (zh) | 降糖降脂降压、改善微循环及免疫的药剂及其制备方法 | |
CN1332688C (zh) | 一种治疗血管性痴呆的药物及其制备方法 | |
CN1115159C (zh) | 一种含紫丹参的药物组合物及其制备方法和应用 | |
CN105727089A (zh) | 含艾叶的药物组合物用于制备治疗肠易激综合症药物中的用途 | |
CN101797365B (zh) | 一种开胸顺气胶囊的制备工艺 | |
CN108578578A (zh) | 一种药物组合物及其制备方法 | |
CN110522798A (zh) | 一种主治冠心病的复方制剂及其制备方法 | |
CN110215474B (zh) | 一种活血化瘀中药组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Mongolian medicine Baolier for treating hyperlipemia and method for preparing same Effective date of registration: 20130829 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2013990000619 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
C56 | Change in the name or address of the patentee | ||
CP02 | Change in the address of a patent holder |
Address after: 028011 west section of Liao River Street, Tongliao economic and Technological Development Zone, the Inner Mongolia Autonomous Region Patentee after: Inner Mongolia Medicine Co., Ltd. Address before: 028007, the Inner Mongolia Autonomous Region, Tongliao, Horqin Road, Tong Cheng Road No. 18 Patentee before: Inner Mongolia Medicine Co., Ltd. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20141011 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2013990000619 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Mongolian medicine Baolier for treating hyperlipemia and method for preparing same Effective date of registration: 20141013 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2014990000845 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160113 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2014990000845 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Mongolian medicine Baolier for treating hyperlipemia and method for preparing same Effective date of registration: 20160113 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2016990000034 |
|
PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20170713 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2016990000034 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Mongolian medicine Baolier for treating hyperlipemia and method for preparing same Effective date of registration: 20170713 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2017990000634 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20181130 Granted publication date: 20080813 Pledgee: China Minsheng Banking Corp Hohhot branch Pledgor: Inner Mongolia Medicine Co., Ltd. Registration number: 2017990000634 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |